Numerous studies revealed that in the hibition of intrarenal renin-angiotensin system (RAS) by using the angiotensin-converting enzyme inhibitors and/or the ATR1 blockers can attenuate progressive glomerulosclerosis in renal disease models and can slow the progression of renal disease in patients with type 2 diabetes [28]. Here, AGTR1 is linked to kidney disorder.